Compass Pathways reported a net loss of $38.5 million for the third quarter of 2024. The company is prioritizing its COMP360 program and reducing its workforce by approximately 30%. The company's cash and cash equivalents were $207 million as of September 30, 2024.
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025.
COMP006 data will now be announced after 26-week time point, expected in the second half of 2026.
Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%.
Cash position of $207 million.
Fourth quarter 2024 net cash used in operating activities is expected to be in the range of $37 million to $43 million. The full-year 2024 net cash used in operating activities is expected to be in the range of $114 million to $120 million. The cash position at September 30, 2024, is expected to be sufficient to fund operating expenses and capital expenditure requirements at least into 2026.
Analyze how earnings announcements historically affect stock price performance